Daro-PET: A phase 2 trial of darolutamide as a prostate-specific membrane antigen (PSMA) expression enhancer in patients with localized prostate cancer.
- Resource Type
- Article
- Source
- Journal of Clinical Oncology; 2024 Supplement 4, Vol. 42, pTPS348-TPS348, 97p
- Subject
- Language
- ISSN
- 0732183X